Anti-PD-1 immunotherapy in advanced metastatic melanoma: State of the art and future challenges
- 1 January 2020
- journal article
- research article
- Published by Elsevier in Life Sciences
- Vol. 240, 117093
Abstract
No abstract availableKeywords
Funding Information
- European Commission (POCI/01/0145/FEDER/007265)
- Fundação para a Ciência e a Tecnologia
- Ministério da Educação e Ciência (PT2020 UID/QUI/50006/2013)
- Instituto Nacional de Ciência e Tecnologia para Excitotoxicidade e Neuroproteção
This publication has 65 references indexed in Scilit:
- The role of BRAF V600 mutation in melanomaJournal of Translational Medicine, 2012
- Biostatistics Primer: What a Clinician Ought to Know: Hazard RatiosJournal of Thoracic Oncology, 2011
- Targeting BRAF for patients with melanomaBritish Journal of Cancer, 2010
- Immune Regulation of CancerJournal of Clinical Oncology, 2010
- Targeting the MAPK pathway in melanoma: Why some approaches succeed and other failBiochemical Pharmacology, 2010
- Skin photoprotection by natural polyphenols: anti-inflammatory, antioxidant and DNA repair mechanismsArchives of Dermatological Research, 2009
- Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathwaysImmunological Reviews, 2008
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008
- Gender-Related Differences in Outcome for Melanoma PatientsAnnals of Surgery, 2006
- UV-induced skin damageToxicology, 2003